Latest News

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

Study finds Gemini and GPT catch oncology chart errors, improving documentation accuracy and patient safety with clinician oversight.

The DNA ImmunoBody therapy improved efficacy when added to ipilimumab and nivolumab, with a registrational phase 3 trial expected to begin later this year.

FDA accepted the NDA for zipalertinib to treat previously treated metastatic NSCLC with EGFR exon 20 insertion mutations. Target action date: 2/27/27.

NCCN now recommends taletrectinib for ROS1+ NSCLC with brain metastases, citing high intracranial response rates in TKI-naive and pretreated patient cohorts.

The FDA has has granted a priority review to zanidatamab-based regimens for the first-line treatment of patients with gastroesophageal adenocarcinoma.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.

Advanced genomic profiling in community oncology uncovers actionable cancer mutations and trial options—yet insurance denials still block access.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

Odronextamab delivers higher responses and longer control in later-line follicular lymphoma versus real-world therapies, new analysis reports.

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

The monoclonal antibody LYT-200 demonstrated promising clinical activity and a favorable safety profile in patients with high-risk myelodysplastic syndrome.

The target date for the FDA's decision on isatuximab via on-body injector is now July 23, 2026.

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in melanoma.

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.

The phase 3 LITESPARK-012 trial failed to meet primary end points of PFS/OS for adding belzutifan or quavonlimab to the standard pembro/lenvatinib doublet.

BBO-11818 has received FDA fast track designation for KRAS-mutant pancreatic cancer, with early phase 1 data showing antitumor activity.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

Phase 1 trial of JANX014, a PSMA-targeted T-cell engager, begins in mCRPC, building on prior safety data to expand treatment strategies.

The FDA has granted a priority review to the supplemental biologics license application for enfortumab vedotin/pembrolizumab to all patients with MIBC regardless of cisplatin eligibility.

Nearly 60% of under-50 cancers are screen-detectable; Ohio State’s BRIDGE program coordinates care, research, and support for younger adults.

FDA oncology updates spotlight SCLC ADC review, NRG1 cholangiocarcinoma filing, new glioma PET imaging, and trial restart.

During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.

Why oncology telehealth stalls: patients cite platform anxiety, few video offers, and in-person trust—pointing to hybrid care.

Combination of interleukin-12 therapy with HAIP chemotherapy showed strong antitumor activity and manageable safety in metastatic CRC with liver metastases.

Darlifarnib may enable the rechallenging of patients with cabozantinib in a combination context for patients with clear cell renal cell carcinoma.